All News
Filter News
Found 796,712 articles
-
PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference - Jan 03, 2024
1/3/2024
PureTech Health plc announced that Daphne Zohar, Founder and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:00 a.m. PST / 12:00 p.m. EST.
-
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
1/3/2024
Agios Pharmaceuticals, Inc. announced that the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent alpha- or beta-thalassemia achieved its primary endpoint of hemoglobin response.
-
Verge Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
1/3/2024
Verge Genomics announced that Verge Genomics’ co-founder and CEO, Alice Zhang, will present at the 42nd Annual J.P. Morgan Healthcare Conference.
-
Alzheon CEO Dr. Martin Tolar to Present ALZ-801/Valiltramiprosate Investigational Oral Alzheimer’s Treatment Program at Nobel Forum at Karolinska Institute in Stockholm, Sweden
1/3/2024
Alzheon, Inc. announced its participation in the Nobel Forum “Challenges for Implementation of New Alzheimer’s Disease Treatments” covering Alzheimer’s therapeutics for the future, at the Karolinska Institute in Stockholm, Sweden from January 18-19.
-
LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patients
1/3/2024
LumiThera Inc. announced an update on the regulatory status of the Valeda® Light Delivery System.
-
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
1/3/2024
Invivyd, Inc. announced that it has requested Emergency Use Authorization from the U.S. Food and Drug Administration for VYD222, a broadly neutralizing, half-life extended monoclonal antibody candidate, for the pre-exposure prevention of COVID-19 in immunocompromised adults and adolescents.
-
Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Merck, known as MSD outside of the United States and Canada, announced that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, Jan. 8, 2024, at 4:30 p.m. PST / 7:30 p.m. EST.
-
South Rampart Pharma to Present at Biotech Showcase 2024
1/3/2024
South Rampart Pharma, Inc. announced that Hernan Bazan, MD, FACS, CEO and Co-Founder of South Rampart Pharma, will present the latest clinical and scientific data on its lead clinical asset at Biotech Showcase 2024 on Tuesday, January 9.
-
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
1/3/2024
Apollomics Inc. announced the completion of enrollment in its Phase 3 bridging study evaluating uproleselan, an investigational, first-in-class E-selectin antagonist, added to a standard chemotherapy regimen for the treatment of adults with relapsed or refractory acute myeloid leukemia.
-
Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader, Paul Grayson, as CEO
1/3/2024
Radionetics Oncology, Inc. announces the completion of a $52.5 million Series A financing.
-
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Immunocore Holdings plc announced that management will participate in a presentation at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
-
Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia
1/3/2024
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced it has submitted a New Drug Application to the U.S. Food and Drug Administration for govorestat for the treatment of Classic Galactosemia.
-
Harvey J. Berger, M.D. Joins Kojin Therapeutics as Chairman, President, and Chief Executive Officer
1/3/2024
Kojin Therapeutics, Inc. announced the appointment of Harvey J. Berger, M.D. as its new chairman, president, and chief executive officer.
-
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers
1/3/2024
Tango Therapeutics, Inc. announced that the first patient has been dosed in the phase 1/2 trial evaluating TNG348 as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant or other HRD+ cancers.
-
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in January: Focus is on TNX-102 SL for the Management of Fibromyalgia Following Positive Topline Results in Second Pivotal Phase 3 Trial
1/3/2024
Tonix Pharmaceuticals Holding Corp. announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present and host investor meetings at the following January investor conferences.
-
Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
1/3/2024
Suzhou Ribo Life Science Co., Ltd. and Ribocure AB announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis.
-
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024
1/3/2024
Chemomab Therapeutics Ltd. announced early completion of patient enrollment in its Phase 2 clinical trial assessing CM-101 as a treatment for primary sclerosing cholangitis.
-
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Monte Rosa Therapeutics, Inc. announced that Markus Warmuth, M.D., Chief Executive Officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PT.
-
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
1/3/2024
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it has reached a definitive agreement to sell its wholly-owned subsidiary, AbCheck s.r.o., to Ampersand Biomedicines.
-
ProMIS Neurosciences, Inc. Announces Leadership Transition
1/3/2024
ProMIS Neurosciences Inc., a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy, announced a strategic leadership change.